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Introduction: Current guidelines for ischemic stroke prevention in atrialﬁbrillation orﬂutter (AFF) recommend
Vitamin K antagonists (VKAs) for patients at high-intermediate risk and aspirin for those at intermediate-low
risk. The cost-effectiveness of these treatments was demonstrated also in elderly patients. However, there are
several reports that emphasize the underuse of pharmacological prophylaxis of cardio-embolism in patients
with AFF in different health care settings.
Aims: To evaluate the adherence to current guidelines on cardio-embolic prophylaxis in elderly (N65 years old)
patients admitted with an established diagnosis of AFF to the Italian internal medicine wards participating in
REPOSI registry, a project on polypathologies/polytherapies stemming from the collaboration between the
Italian Society of Internal Medicine and the Mario Negri Institute of Pharmacological Research; to investigate
whether or not hospitalization had an impact on guidelines adherence; to test the role of possible modiﬁers of
VKAs prescription.
Methods:We retrospectively analyzed registry data collected from January to December 2008 and assessed the
prevalence of patients with AFF at admission and the prevalence of risk factors for cardio-embolism. After
stratifying the patients according to their CHADS2 score the percentage of appropriateness of antithrombotic
therapy prescription was evaluated both at admission and at discharge. Univariable and multivariable logistic
regression models were employed to verify whether or not socio-demographic (age N80 years, living alone)
and clinical features (previous or recent bleeding, cranio-facial trauma, cancer, dementia) modiﬁed the
frequency and modalities of antithrombotic drugs prescription at admission and discharge.
Results: Among the 1332 REPOSI patients, 247 were admitted with AFF. At admission, CHADS2 score was≥2 in
68.4% of patients, at discharge in 75.9%. Among patients with AFF 26.5% at admission and 32.8% at discharge
were not on any antithrombotic therapy, and 43.7% at admission and 40.9% at discharge were not taking an
appropriate therapy according to the CHADS2 score. The higher the level of cardio-embolic risk the higher was
the percentage of antiplatelet- but not of VKAs-treated patients. At admission or at discharge, both at
univariable and at multivariable logistic regression, only an age N80 years and a diagnosis of cancer, previous
or active, had a statistically signiﬁcant negative effect onVKAs prescription.Moreover, only a positive history of
bleeding events (past or present)was independently associated to no VKAprescription at discharge in patients
whowere on VKA therapy at admission. If heparin was considered as an appropriate therapy for patients with
indication for VKAs, the percentage of patients admitted or discharged on appropriate therapy became
respectively 43.7% and 53.4%.
Conclusion: Among elderly patients admitted with a diagnosis of AFF to internal medicine wards, an
appropriate antithrombotic prophylaxis was taken by less than 50%, with an underuse of VKAs prescription
independently of the level of cardio-embolic risk. Hospitalization did not improve the adherence to guidelines.
© 2010 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.cci).
di Medicina Interna.
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disorder affectingmainly elderly people. Its prevalence rapidly increases
after the sixth decade of life and is about 10% in people more than
80 years of age [1–3]. AFF is associated with a 4–5 fold increase in the
risk of ischemic stroke at all ages, and the percentage of ischemic
strokes attributable to AFF rises with advancing age up to nearly
25% in the class from 80 to 89 years [4–6]. In patients with AFF oral
anticoagulant therapy with vitamin K antagonists (VKAs) prevents
cardio-embolism, with a relative risk reduction of ischemic stroke of
more than 60% [7,8]. Unfortunately, in the frame of clinical trials VKAs
also increase the risk of major bleeding by 0.3–0.5%/year, and the risk of
intracranial hemorrhage by 0.2%/year [7,9]. Bleeding rates are even
higher outside the boundaries of controlled trials [10,11]. Major
determinants of the risk of bleeding are intensity of anticoagulation
(measured by means of the International Normalized Ratio of the
prothrombin time, INR), unpredictable anticoagulant effect in the
induction phase (ﬁrst 3 months of treatment) [12–14] and some patient
characteristics (age, history of bleeding, comorbidities such as malig-
nancy and renal failure) [15–18]. Also aspirin is effective in preventing
cardio-embolism, but 3-fold less than VKAs and with no clear advantage
in terms of safety [8]. It is not yet clear if the combination of aspirin and
VKAs is more effective than either drug in patients with AFF, but it does
deﬁnitely increase the risk of bleeding [19]. Finally, the only other
antiplatelet agents evaluated in AFF were indobufen and clopidogrel.
Indobufen had no advantage when compared to warfarin versus a
composite clinical end-point including incident stroke [20]. In patients
not eligible for VKAs, the addition of clopidogrel to aspirin reduced the
risk of major vascular events, especially stroke, but increased the rate of
major bleeding [21], the combination being clearly less effective than
VKAs alone [22]. Extended-release dipyridamole plus aspirin were
compared to clopidogrel for recurrent stroke in patients with a recent
ischemic stroke, with no evidence of superiority of either treatment,
not even in the subgroup of patients with a stroke of cardio-embolic
origin (near 2% in each arm) [23].
With this as background, most guidelines currently recommend
antithrombotic prophylaxis for patients with paroxysmal and perma-
nent AFF, tailored according to the level of cardio-embolic risk as
calculated on the basis of known risk factors for ischemic stroke in AFF
[24–26]. Despite growing use of VKAs in patients with AFF from early
1980s to mid–1990s, and although the cost-effectiveness of this
prophylactic strategy is clearly demonstrated particularly in elderly
people [27,28], the adherence to guidelines is still very poor in
different healthcare settings (community, in- and outpatients, nursing
homes, academic hospitals), with a clear trend for decreasing use of
VKAs with increasing age [29–35].
The aim of this analysis was to assess the modalities of cardio-
embolic prophylaxis and to verify the adherence to guidelines in
patientswith AFF at admission to and at discharge from Italian internal
medicine wards participating to a prospective registry of elderly
patients. We also attempted to establish which factors modiﬁed
adherence to antithrombotic therapy.
2. Methods
2.1. Data collection
We analyzed retrospectively the data collected from January 2008
to December 2008 in the frame of REPOSI, an independent research
project on polypathologies/polytherapies based upon a prospective
registry and stemming from the collaboration between the Italian
Society of Internal Medicine (SIMI) and the Mario Negri Institute for
Pharmacological Research. The project has set up a network of
internal medicine and geriatric wards that chose to participate to the
registry in order to generate information about elderly patientsaffected by multiple diseases and prescribed with multiple drugs.
Patients were eligible for REPOSI if: 1) they were admitted to one of
the 36 participating Italian internal medicine (n=32) and geriatric
wards (=4) during one of the 4 weeks chosen for recruitment (in
February, June, September and December 2008); 2) their age was
65 years or older; 3) they gave informed consent. Each ward had to
enroll at least the ﬁrst 10 consecutive eligible patients during each
index week. For each patient a web-based case report form was ﬁlled
in with information about socio-demographic features, cause of
hospitalization, diagnoses and treatment both at admission and at
discharge, clinical events during hospitalization and outcome. A ﬁnal
database was created, checked and cleaned at the Mario Negri
Institute for Pharmacological Research and shared with all the
participants in the project. The management of the central repository
and the participation of the recruiting units to the registry were
voluntary and not sponsored.
2.2. Study population
For the purpose of this analysis we selected among the patients
recruited in REPOSI only those who had a diagnosis of AFF (paroxysmal
or persistent) at admission. The patients were identiﬁed in the database
by the International Classiﬁcation of Diseases – Ninth Revision (ICD9)
codes 427.31 or 427.32. Patients with AFF as a new diagnosis during
the index hospitalization were not included in this analysis in order to
make the study population more homogeneous, to focus on the long-
term pharmacological prophylaxis of cardio-embolism and to investi-
gatewhether or not hospitalization affected the frequency andmodality
of application of antithrombotic prophylaxis.
2.3. Assessment of cardio-embolic risk and appropriateness of antithrombotic
prophylaxis
In order to classify patients with AFF according to their risk of
cardio-embolic events, we used the CHADS2 score [7,36] that assigns
one point each of the following risk factors: congestive heart failure or
a severe impairment of left ventricular systolic function (C); history
of hypertension (H); ageN75 years (A); diabetes mellitus (D). Two
points are attributed to a prior ischemic stroke, TIA or systemic
embolism (S2). The higher is the total score for a patient, the higher is
his/her risk of cardio-embolism. The CHADS2 score was calculated at
admission to the hospital for the included patients by looking for the
risk factors in the database sections collecting demographic char-
acteristics and diagnoses (ICD9 classiﬁcation). The CHADS2 score was
recalculated at discharge and updated if further risk factors were
newly detected during hospitalization.
For the evaluation of antithrombotic prophylaxis prescribed at
admission and at discharge, we considered as anticoagulants VKAs and
as antiplatelet drugs aspirin, clopidogrel, ticlopidine and other agents
with antiaggregating action; they were coded in the database section
collecting treatment data according to the Anatomical Therapeutic
Chemical (ATC) classiﬁcation as B01AA and B01AC, respectively. Since
our goal was to focus on long term cardio-embolic prophylaxis, before
analysis of the database we chose not to consider in the analysis
any parenteral antithrombotic agents given during hospitalization.
Practice guidelines of the American College of Chest Physicians
(ACCP) (8th edition, 2008) [25] were followed to assess the ap-
propriateness of antithrombotic prescription based on the cardio-
embolic risk. The ACCP recommends long-term anticoagulation with
VKAs for patients with AFF and CHADS2 score≥1 (recommendation
grade 1A); for patients with CHADS2 score equal to 1, aspirin (at a
dose of 75–325 mg/day) is proposed as an alternative (grade 1B).
Aspirin is also recommended for patients with a low risk of ischemic
stroke (CHADS2=0). Similar recommendations are contained in the
practice guidelines of the American College of Cardiology/American
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[24].
2.4. Modiﬁers of VKAs prescription
We examined the REPOSI database to search for factors that might
be involved in making the clinical decision process or reduce patient
compliance, on the basis of literature reports [9,37,38] and clinical
judgment, and we tested their association with VKAs intake at
admission to the hospital and prescription at discharge. The REPOSI
database provided data on the following variables: sex, ageN80 years,
living alone, taking multiple drugs (more than 8), bleedings (total and
intracranial), cranio-facial traumas related to falls, solid and hemato-
logic tumors, vertigo/vertiginous syndromes/dizziness/ataxia/difﬁcult
walking (e.g. a high risk of fall), dementia/cognitive impairment,
being bedridden/immobilization syndrome. This information was
recorded at hospital admission or as having occurred thereafter
during the hospital stay. The diseases were identiﬁed in the database
according to the ICD9 classiﬁcation.
2.5. Statistical analysis
The prevalence of patients with a preexisting diagnosis of AFF at
hospital admission was calculated on all patients included in the
REPOSI registry. For patientswith AFFwe calculated: 1) the prevalence
of risk factors for cardio-embolism at admission and at discharge;
2) the prevalence of factors likely to inﬂuence VKAs prescription;
3) the prevalence of prescription of antithrombotic regimens in
different CHADS2 risk groups, and the crude rate of appropriate
prescription of VKAs before and after hospitalization.
Univariable andmultivariable logistic regressions (including all the
possible modiﬁers listed above) were modeled to test the association
between prescription of VKAs in patients with AFF (outcome variable)
and socio-demographic or clinical characteristics. We formally tested
for a centre effect on the type of therapy prescribed at discharge by
using a set of dummy variables in the logistic model. In order to take
into account themulti-center origin of the REPOSI data, we planned to
adopt robust variance estimates that were obtained in all regression
models by the Huber/White/sandwich estimator which considers
observations as independent across groups (centers).
Two sensitivity analyseswere performed: 1) the rate of appropriate
prescription of antithrombotic therapy in different CHADS2 risk groups
was recalculated after excluding patients with factors found to be
associated with lack of VKA prescription; 2) the rate of appropriate
prescription of antithrombotic therapy and the effect of the possible
modiﬁers of VKAs prescription were recalculated after considering
heparin as an appropriate therapy for patients with an indication for
VKAs.
Patients died during hospitalization were excluded from the
analyses at discharge. Patients coming from or moving to other wards
or nursing homes were excluded from the analyses on predictors of
VKAs prescription, in order to make more homogeneous the sample
analyzed.
STATAwas used to perform all the analyses (version 9.2, Statacorp,
College Station, Tx, US).
3. Results
During the 4 weeks selected for the REPOSI data collection, the 36
participating wards enrolled 1332 patients. The majority of these
patients came from their homes (n=1178, 88.4%) after attending or not
the emergency room; others were transferred to the internal medicine
or geriatric ward from another ward (n=83, 6.0%) or from a nursing
home (n=48, 3.6%); for 23 patients data about origin were missing.
Sixty-six of 1332 patients died during hospitalization (5.0%), 111 were
moved to another ward/hospital, to nursing homes or rehabilitationstructures (8.3%), 1155 were discharged back home (86.7%). Fig. 1
shows the steps that led to the selection of the population included in
this analysis from the whole REPOSI study population. One hundred
and twenty-seven were males (51.4%), 120 were females (48.6%); they
had a mean age of 81.3±7.5 years (median 81 years, range 66–100).
3.1. Cardio-embolic risk stratiﬁcation and antithrombotic therapy
There was a high prevalence of cardio-embolic risk factors among
patients with AFF. One hundred ninety-ﬁve patients (78.9%) were
more than 75 years old. At admission, 144/247 (58.3%) had hyperten-
sion, 63/247 (25.5%) were diabetic, 65/247 (26.3%) had a severe
impairment of left ventricular systolic function, 11/247 (4.4%)
reported a prior episode of ischemic stroke, TIA or systemic embolism
in their clinical history.
Table 1 shows the stratiﬁcation of the patients with a known
diagnosis of AFF according to CHADS2 score, at admission and at
discharge, and the prevalence of antithrombotic strategies/no therapy
in the different risk groups. Considering inappropriate a prophylactic
strategy adopted without following the current guidelines according
to the assessed level of risk, and assuming that the other antiplatelet
agents were equivalent in efﬁcacy to aspirin, the proportion of
patients on appropriate antithrombotic therapy at admission was
107/245 (43.7%), and 56/168 (33.3%) when including only patients
with CHADS2 score≥2; at discharge, 95/232 (40.9%), and 64/176
(36.4%) when including only patients with CHADS2 score≥2. Very
similar results at admission and discharge were also obtained when
patients coming from and moved to another hospital ward were
excluded. When data at admission and discharge for patients with
higher cardio-embolic risk (CHADS2 score≥2) were merged, 15/104
(14.4%) of patients not taking VKAs at admission were prescribed
with this therapy at discharge and 12/57 (21.0%) of patients taking
this therapy at admission were not prescribed it at discharge.
3.1.1. Association between possible modiﬁers and VKAs prescription
Table 2 shows the antithrombotic therapies used in the presence of
these possible modiﬁers (results are limited to most prevalent ones:
number of cases at least 30). Fig. 2 (based upon data obtained at
admission) and Fig. 3 (at discharge) compare the prevalence of the
possible modiﬁers in patients on therapy and in those not on therapy
with VKAs. At admission and discharge, only an ageN80 years and
a diagnosis of cancer (previous or still active), had a statistically
signiﬁcant (or close to statistical signiﬁcance in patients with CHADS2
score≥2) negative effect on VKAs prescription at univariable logistic
regression. Patients already admitted or discharged while taking
more than 8 drugs were more likely on therapy with VKAs, with a
statistically signiﬁcant association.
When tested in multivariable regression accounting for the multi-
centre study design and including all the possible predictors (sex,
ageN80 years, living alone, takingN8 drugs, bleedings, cranio-facial
traumas, solid and hematologic tumors, risk of fall, dementia), age and
malignancy retained their signiﬁcant negative effect both at admission
and discharge. Polypharmacotherapy was not statistically signiﬁcant
associated with prescription of VKAs. In patients with CHADS2
score≥2, malignancy had a non signiﬁcant negative association,
both at admission and at discharge; ageN80 years had a statistically
signiﬁcant negative effect at discharge; living alone was associated
with statistically signiﬁcance to prescription of VKAs at discharge.
None of the centers had a signiﬁcant effect on prescription of
VKAs at discharge (likelihood-ratio test for the model accounting for
the centre effect 38.6, p=0.09).
3.1.2. Association between modiﬁers and in hospital withdrawal of VKAs
Whenweanalyzed the role of possiblemodiﬁer of VKAprescription
at discharge in patients on VKA therapy at admission, only a positive
history for bleeding events (past or occurred during hospitalization)
Fig. 1. Selection, origin and outcome of patients (pts) with a known diagnosis of atrial ﬁbrillation or ﬂutter (AFF) at admission to the internal medicine or geriatrics wards among
participants in REPOSI.
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95% conﬁdence intervalsb0.01–0.38; p value=0.005); the OR adjust-
ed for the other covariates was 0.09 (95% conﬁdence intervals 0.01–
1.01; p value=0.051).
3.2. Sensitivity analyses
We ﬁrst recalculated rates of appropriate prescription after
removal of patients with modiﬁers that were negatively associated
to VKAs prescription. When patients more than 80 years old and with
cancer were excluded from the analysis, the frequency of adherence
to guidelines was 57.1% at admission (50.0% among patients with
CHADS2 score≥2) and 56.4% at discharge (56.1% among patients with
CHADS2 score≥2). We then tested the usage of heparin in patients
with indication for VKAs therapy. At admission, 11/147 (7.5%)
patients with CHADS2 score≥1 not taking VKAs were on therapy
with heparin (6 out of these coming from their home). Heparin was
prescribed to 37/141 (26.2%) patients with CHADS2 score≥1
discharged without VKAs prescription (29 out of these dischargedTable 1
Percentages of patients with AFF according to their level of cardio-embolic risk and to




VKAs Apsc VKAs+APsd No therapy
All N=245a
(232b)
33.9 (34.5) 37.1 (30.6) 2.5 (2.2) 26.5 (32.8)
CHADS2≥2 68.4 (75.9) 30.9 (34.1) 40.5 (34.1) 2.4 (2.3) 26.2 (29.5)
CHADS2=1 25.9 (21.1) 42.9 (38.8) 31.7 (18.4) 1.6 (2.0) 23.8 (40.8)
CHADS2=0 5.7 (3.0) 28.6 (14.3) 21.4 (28.6) 7.1 (0) 42.9 (57.1)
VKAs, Vitamin K Antagonists; APs, Antiplatelet drugs.
a 2 patients with missing data on therapy.
b 15 patients died during hospitalization.
c Among patients on therapy with an AP at admission, 77.3% were on aspirin, 21.6%
were on ticlopidine; only 1 patient (0.01%) was on indobufen. At discharge, 72.5% were
on aspirin, 26.1% were on ticlopidine; the patient on therapy with indobufen was
conﬁrmed with this drug. 5 patients on therapy with two APs: at admission, 2 were on
aspirin and clopidogrel, 1 was on aspirin and ticlopidine; 2 were discharged with
double antiplatelet therapy (aspirin and clopidogrel).
d At admission, half of patients on therapy with VKAs plus an AP were on aspirin,
another half on ticlopidine; all the patients discharged with VKAs plus an antiplatelet
were on aspirin.to home). Considering arbitrarily heparin an appropriate therapy for
patients with indication for VKAs, the proportion of patients on
appropriate therapy became 107/245 (43.7%) at admission and 132/
247 (53.4%) at discharge.
4. Discussion
In this retrospective analysis of the REPOSI data, obtained in a
prospective cohort of elderly patients with a known diagnosis of AFF
hospitalized in Italian internal medicine and geriatric wards in the
year 2008, cardio-embolic prophylaxis was far from adherence to the
ACCP guidelines in more than half of the cases, both before and after
hospitalization. In particular, VKAs were underused irrespective of the
level of cardio-embolic risk, and hospitalization did not lead to an
improvement in the rate of adherence to guidelines. When investi-
gating the possible role of patient demographic or clinical features
on VKAs intake/prescription, a statistically signiﬁcant inverse associ-
ation was found between VKA prescription and both an ageN80 years
old and a past or recent history of malignancy, and between a past or
recent history of bleeding and VKAs withdrawal at discharge in
patients who were taking VKAs at admission.
Our results are in substancial accordance with those obtained in
other Italian clinical settings. Ageno et al. [39] reported a very low
frequency of antithrombotic therapy among hospitalized patients with
AFF one year after discharge. Monte et al. [40] found low rates of VKAs
prescriptionandanassociationbetween theunderuseof antithrombotic
agents after discharge and a poorer outcome. Ferro et al. [41] described a
similar scenario amongpatients athigh cardio-embolic riskat admission
to a single clinical centre. Our approach provides amore comprehensive
evaluation, becausedatawere collectedbothat admission anddischarge
with the aim to investigate both the attitude to prescription at the
primary care level and any variation related to hospitalization. Even if
wewere not able to verify if not being on VKAs at admissionwas due to
lack of medical prescription or to poor patient compliance, we found
rates of prescription of VKAs/antiplatelet drugs/no therapy very similar
to those published by Mazzaglia et al. [42], who analyzed primary
care data. Like them, an increasing use of antiplatelet drugs, but not of
VKAs, was found in association with a worsening cardio-embolic risk
proﬁle. Another novelty of our study consists in having collected data
from several hospitals located in different regions of Italy. Finally, the
absence of any priori exclusion criteria (e.g. no upper limit of age for
Table 2
Types of cardio-embolic prophylaxis in patients with AFF according to the most prevalent factors postulated to affect VKAs prescription (in brackets the ﬁgures in patients with
CHADS2≥2)*.
At admission At discharge
(N=217; CHADS2≥2: N=146) (N=213; CHADS2≥2: N=162)
No therapy APs VKAs or VKAs+APs Total number No therapy APs VKAs or VKAs+APs Total number
AgeN80 years, % 19.5 (21.6) 51.3 (50.0) 29.2 (28.4) 115 (89) 28.3 (27.4) 42.5 (45.3) 29.2 (27.4) 113 (95)
Male, % 23.5 (24.1) 37.4 (40.5) 39.1 (35.4) 115 (79) 29.2 (24.1) 32.7 (36.8) 38.0 (39.1) 113 (87)
Female, % 26.0 (25.8) 37.0 (39.4) 37.0 (34.8) 100 (66) 34.0 (32.0) 28.0 (33.3) 38.0 (34.7) 100 (75)
Living alone, % 38.2 (38.1) 23.6 (28.6) 38.2 (33.3) 56 (43) 30.8 (26.8) 21.1 (26.8) 48.1 (46.4) 52 (41)
TakingN8 drugs, % 16.7 (18.5) 27.8 (33.3) 55.5 (48.1) 36 (27) 14.0 (14.6) 34.0 (41.5) 52.0 (43.9) 50 (41)
Malignancy, % 48.5 (50.0) 33.3 (37.5) 18.2 (12.5) 33 (16) 50.0 (40.0) 32.5 (40.0) 17.5 (20.0) 40 (25)
VKAs, Vitamin K Antagonists; APs, Antiplatelet drugs; AFF, Atrial Fibrillation Flutter.
#The data for the other predictors were not reported because of the low prevalence: at admission, 2 patients had a bleeding event in their clinical history (0.9%); 3 had had a cranio-
facial trauma (1.4%), 15 had a diagnosis of dementia/cognitive impairment (6.9%); at discharge, 12 patients had a bleeding event in their clinical history or occurring during
hospitalization (5.6%); 5 had had a cranio-facial trauma in their clinical history or occurring during hospitalization (2.3%), 17 had a diagnosis of dementia/cognitive impairment
(8.0%); none of patients with AFF had a risk of fall related to a diagnosis of vertigo/vertiginous syndromes/dizziness/ataxia/difﬁcult walking, or had a diagnosis of immobilization
syndrome, either at admission or at discharge.
*Patients coming from or moved to other wards or nursing homes were excluded.
520 M. Marcucci et al. / European Journal of Internal Medicine 21 (2010) 516–523inclusion) and the internal medicine context allowed us to analyze an
elderly population of complex patients on multiple drug therapy that
better reﬂects those usually managed in internal medicine wards.
One of the main ﬁndings is the lack of a signiﬁcant impact of
hospitalization on the adherence to current guidelines. The proportion
of patients with CHADS2 score≥2 on therapy with VKAs actually
increased at discharge as compared to admission (while the proportion
of patients with CHADS2 score≥2 on therapy with antiplatelet
decreased), but the absolute percentage was still unsatisfactory and
the percentage of patients discharged without any antithrombotic
therapy was surprisingly high, irrespective of the level of cardio-
embolic risk. On the other hand, there were a relevant percentage of
patients with CHADS2 score=0 who were on therapy with VKAs even
if not recommended (and none of these had other diseases justifying
anticoagulant prescription). Our results suggest that the level of cardio-
embolic risk is not the main (or at least not the only), determinant of
the therapeutic choice in this population of elderly patients. On the
other hand, cardio-embolic risk factors should be considered by the
physician as factors associated to the risk of bleeding, because all
the bleeding events recorded in this study among AFF patients did
occur in patients with CHADS2 score≥1.
We only partially conﬁrmed the role of some clinical and socio-
demographic factors as negative modiﬁers of VKAs prescription. We
found a trend to not prescribe VKAs in patients older than 80 years,
even if older age is a known risk factor for cardio-embolic events.Fig. 2. Effect of possible modiﬁers of VKAs prescription at admission: results of univariable lo
extracranial bleeding (hematuria) occurred; among patients not on VKAs therapy one intracr
*p=0.008; ‡p=0.020; ∫p=0.029; **p=0.063; ∫∫p=0.066.These results are perhaps explained by the physician concern, giving
more weight to the high age-related risk of bleeding and to the low
compliance in elderly patients than to the similarly high age-related
cardio-embolic risk. This ﬁnding holds a particular relevance consider-
ing the recent debate on the development a new scoring system based
upon age alone as an independent predictor of high cardio-embolic
risk [43]. Cancer patients with AFF might be less frequently eligible to
oral anticoagulation because of a higher risk of bleeding, or because
of the fear of drug interaction with chemotherapy or analgesics.
Sometime the shorter life expectancy, which magniﬁes the problems
related to the management of VKA therapy, might lead the physician to
choose heparin for cardio-embolic prophylaxis in cancer patients even if
this choice is not evidence-based. This reasoning could explain the
results of our sensitivity analysis on the use of heparin as equivalent to
VKAs. The role of these modiﬁers of VKAs prescription focuses the
attention on the issue of the safety. Previous reports have demonstrated
that in clinical practice patients with AFF often have characteristics
that led to their exclusion from the trials that are the basis of available
scientiﬁc guidelines [44]. This could be translated as having a different
safety proﬁle compared to the patients included in those trials, and
could make reasonable not to treat them even in presence of a high
cardio-embolic risk.
One of the limitations of our study is the relatively small size of the
sample and hence the low power of some analyses, especially when
the role of some predictors poorly represented in the database wasgistic regression models. Legend: OR, odds ratio.#Among patients on VKAs therapy, one
anial bleeding. †The wideness of conﬁdence intervals is due to the low number of cases.
Fig. 3. Effect of possible modiﬁers of VKAs prescription at discharge: results of univariable logistic regression models. Legend: OR, odds ratio. #Among patients on VKAs therapy, one
extracranial bleeding (hematuria) occurred; among patients not on VKAs therapy, 4 out of 11 bleeding events were intracranial (3 out of 5 bleeding events were intracranial when
considering patients with CHADS2≥2). †The width of conﬁdence intervals is due to the low number of cases p=0.012; ‡p=0.021; ∫p=0.004; **p=0.004; ∫∫p=0.053.
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have led to apparently meaningless results, such as the association
between VKAs prescription and a history of bleeding (see Table 3),
even if this ﬁnding could be alternatively explained with the high
prevalence of minor bleeding inherent in VKAs treatment. Other
important limitations derive from the retrospective nature of the
analysis, so that only the role of the possible predictors for which data
were available in the REPOSI database could be investigated. For
example, the choice of ICD9 classiﬁcation for diagnostic coding did not
allow us to distinguish between paroxysmal and permanent AFF,
while clinical practice and previous ﬁndings [41] suggest that patients
with chronic AFF are more likely to be anticoagulated. In general,
information provided by a regression analysis, even if adjusted for
several covariates, is restricted to the factors put in the equation. In
addition, we lacked INR values at admission in order to establish
whether or not patients were on effective anticoagulation, and lack of
follow up after discharge did not allow us to verify the association
between adhesion to guidelines and a more favorable long term
outcome, as others have done [40,45]. Finally, a further limitationmay
be the lower than expected prevalence of prior cerebro-vascular
events, which was probably due to under-reporting. However, under-
reporting of cerebro-vascular accidents would have led to underesti-
mation of the CHADS2 score, and hence to bias our results in the
direction of greater underestimation on the under-treatment of patients
at high cardio-embolic risk.
Despite these limitations, our study adds arguments to the debate
on the actual applicability of evidence-based therapeutic guidelines and
on the necessity to implement them according to new paradigms [46].
The persistence of a generally poor adherence to guidelines in clinical
practice should be a stimulus to increase educational programs for
physicians. The situation should also encourage to choose in clinical
trials less selected patients, in order to get an evidence based more
closely to the real world of the patient with AFF [37,47].
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Alberto Tedeschi, Raffaella Rossio (Medicina Interna 2, Fondazione
IRCCS Ospedale Maggiore, Milano); Guido Moreo, Barbara Ferrari
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AntonioMammarella, Valeria Raparelli (Medicina Interna, Università La
Sapienza, Roma); Stefania Rondinella, Iolanda Giannico (Medicina
Metabolica, Università di Modena e Reggio Emilia); Leonardo Rasciti,
Silvia Gualandi (Medicina Interna, Policlinico S. Orsola Malpighi,
Bologna); Valter Monzani, Valeria Savojardo (Medicina d'Urgenza,IRCCS Fondazione Ospedale Maggiore, Milano); Giovanna Fabio, Silvia
Colombo (Medicina Interna 1A, Fondazione IRCCS Ospedale Maggiore,
Milano); Alessandra Quercioli, Alessandra Barreca (Medicina Interna 1,
Università di Genova); Emanuele Durante-Mangoni, Daniela Pinto
(Medicina Interna, Seconda Università di Napoli); Elena Incasa,
Emanuela Rizzoli (Medicina Interna, Azienda USL, Ferrara); Massimo
Vanoli, Gianluca Casella (Medicina Interna, Azienda Ospedaliera di
Lecco, Ospedale diMerate);GiuseppeMusca,Olga Cuccurullo (Medicina
Interna, P.O. Cetraro, ASP Cosenza); Giuseppe Famularo, Maria Rosaria
Sajeva (Medicina Interna 1, Azienda Ospedaliera San Camillo Forlanini,
Roma); Antonio Picardi, Dritan Hila (Medicina Clinica-Epatologia,
Università Campus Bio-Medico, Roma); Renzo Rozzini, Alessandro
Giordano (Fondazione Poliambulanza, Brescia); Antonio Bonelli,
Gaetano Dentamaro (Medicina, Ospedale Madonna delle Grazie,
Matera); Giulia Gobbo, Massimo Cazzaniga (Medicina Interna, IRCCS
Policlinico SanDonato, Università diMilano); Piergiorgio Gaudenzi, Lisa
Giusto (Medicina ad Alta Rotazione, Azienda Ospedaliera Universitaria,
Ferrara); Damiano Rizzoni, Luana Castoldi (ClinicaMedica, Università di
Brescia); DanielaMari, GiulianaMicale (Medicina Generale ad indirizzo
Geriatrico, IRCCS Istituto Auxologico Italiano, Milano); Emanuele
Altomare, Gaetano Serviddio (Medicina Interna, Università di Foggia);
Carlo Longhini, Cristian Molino (Clinica Medica, Azienda Mista
Ospedaliera Universitaria Sant'Anna, Ferrara); Silvia Deidda, Luciana
Maria Cuccuru (ClinicaMedica,AziendaMistaOspedalieraUniversitaria,
Sassari); Michela Quagliolo, Giuseppe Riccardo Centenaro (Medicina 1,
Ospedale diMelegnano, Vizzolo Predabissi, Milano); Anna Laura Pasqui,
Luca Puccetti (Medicina Interna, Azienda Ospedaliera Universitaria Le
Scotte, Siena); Giampiera Bertolino, Piergiorgio Cavallo (Dipartimento
di Medicina Interna, Fondazione IRCCS Policlinico San Matteo, Uni-
versità degli Studi di Pavia); Daniele Bertolini, Nicola Lucio Liberato
(Medicina Interna, Ospedale CarloMira, Casorate Primo, Pavia); Antonio
Perciccante, Alessia Coralli (Medicina, Ospedale San Giovanni-Decollato-
Andisilla, Civita Castellana); Luigi Anastasio, Leonardo Bertucci (Medicina
Generale, Ospedale Civile Serra San Bruno); Ana Macura, Davide
Matino (Dipartimento di Medicina Interna, Ospedale Santa Maria della
Misericordia, Università di Perugia); Cosimo Morabito, Roberto Fava
(Medicina, Ospedale Scillesi d'America, Scilla); Antonino Tuttolomondo,
Riccardo Di Sciacca (Medicina Interna e Cardioangiologia, Università degli
Studi di Palermo); Andrea Semplicini, Giacomo Magagnotti (Clinica
Medica 4, Università di Padova); Alessandra Fiorentini, Cristina Toﬁ
(Geriatria, Ospedale di Monteﬁascone); Carlo Cagnoni, Antonio Manucra
(UO Medicina e Primo Soccorso, Ospedale di Bobbio, Azienda USL di
Piacenza); Giuseppe Romanelli, (UO Geriatria, Spedali Civili di Brescia);
Michele Cortellaro, Maria Rachele Meroni (Medicina 3, Ospedale Luigi
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Fondazione IRCCS Ospedale Maggiore e Università di Milano).
Learning points
• Antithrombotic prophylaxis in patients with AFF is known to be
efﬁcacious and safe when prescribed according to the degree of
cardio-embolic risk.
• There is evidence in different healthcare settings of a low rate of
adherence to guidelines on antithrombotic therapy for patients with
AFF.
• We conﬁrmed the underuse of antithrombotic therapy, namely of
VKA, among elderly patients with AFF admitted to 36 Italian internal
medicine wards, without a positive impact of hospital admission on
the rate of adherence to guidelines.
• Considering that various socio-demographic and clinical factors other
than those used to stratify the cardio-embolic risk may inﬂuence the
decision to prescribe VKAs, a signiﬁcant association was found
between a history of cancer or previous and current bleeding and
omissionofVKAsprescription at admission to the hospital aswell as at
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